Squamous cell carcinoma of head and neck
Not recruitingStudy of Lenvatinib and Pembrolizumab for Patients with Recurrent or Metastatic Head and Neck Cancer After Platinum and Immunotherapy Treatment
Study of Lenvatinib and Pembrolizumab for Patients with Recurrent or Metastatic Head and Neck Cancer After Platinum and Immunotherapy Treatment
- Disease:Squamous cell carcinoma of head and neck
- Substances:CapecitabineDocetaxel+3
Spain- Participants:18–64 years · 65+ years
- Substances:Capecitabine
- Sponsor:Merck Sharp & Dohme LLC











